RVL Pharmaceuticals plc (RVLP)
RVL Pharmaceuticals plc operates in the Biotechnology industry of the Healthcare sector, headquartered in Bridgewater, NJ, US. The stock last traded at $0.03, down 32.05% on the session, giving a market capitalisation of $3.1M. On trailing twelve-month figures it carries a trailing P/E of -0.05, a net margin of -104.0%. Its beta of 1.09 implies it has historically moved more than the broad market.
RVL Pharmaceuticals plc operates as a specialized pharmaceutical firm, concentrating on the creation and commercialization of medicinal products. These offerings target patient populations with unmet needs within the fields of ocular health and medical aesthetics across the United States, Argentina, and Hungary. Among its key commercialized products is Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution specifically developed for adults experiencing acquired blepharoptosis, or drooping eyelids. The company, whose corporate headquarters are located in Bridgewater, New Jersey, underwent a name change in January 2022, transitioning from its former identity as Osmotica Pharmaceuticals plc.
RVL Pharmaceuticals plc is most often compared with the following Healthcare names: